Galapagos NV has successfully completed a Phase I trial of its drug candidate GLPG0259 for rheumatoid arthritis (RA). The drug showed good safety in healthy volunteers and an excellent pharmacokinetic profile, which supports once-daily oral dosing, according to the company. GLPG0259 is a new mechanism-of-action inhibitor of the protein kinase MAPKAPK5, which represents a new approach for the treatment of RA. The double-blind, single-ascending and multiple dose study was conducted in 34 health...